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Anthracyclines and platinum derivates are active drugs for advanced endometrial carcinoma (AEC), but new schedules with higher
efficacy and better tolerability are needed. A phase II study was conducted to describe activity and tolerability of carboplatin
(C)þpegylated liposomal doxorubicin (PLD) in patients with AEC. Patients with chemonaive AEC, PS p2, aged o75 years, with at
least one measurable lesion were eligible. Treatment was C (area under curve 5)þPLD (40mgm
 2) on day 1 every 4 weeks, up to
six cycles. Forty-two patients were needed in a single-stage design, with at least 13 objective responses to define the treatment active.
Forty-two patients were enrolled. Median age was 64 years (31–74). A total of 64% of patients were recurrent while 36% were
advanced. Three complete (7%) and 22 partial responses (52%) were observed, for an overall response rate of 59.5% (95% exact CI:
43.3–74.3). One death potentially related to treatment was recorded (death at home for unknown reasons after 6th cycle). Other
relevant toxicities (% of patients) were grade 3/4 neutropaenia 33%/14%, febrile neutropaenia 5%, grade 3/4 thrombocytopaenia
17%/5%, grade 3/4 anaemia 31%/2%. Skin toxicity was mild: grade 1 14%, grade 2 10%, grade 3 5%. Hair loss: complete 5%, partial
12%. The combination of carboplatin and PLD shows good activity and favourable toxicity as first-line chemotherapy of patients with
AEC, deserving further studies in this setting.
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Endometrial carcinoma is the most common invasive malignancy
of the female genital tract. Most patients with the disease present
with early stage, have a good prognosis and can be cured with
surgery. On the other hand, patients with advanced or recurrent
disease have a worse prognosis, and results obtained with systemic
therapy are far from being impressive.
Recent systematic reviews of randomised clinical trials show
that there is a limited body of evidence available to help clinicians
make decisions about the treatment of advanced or recurrent
endometrial cancer (Carey et al, 2006; Polyzos et al, 2006).
Doxorubicin, with or without cisplatin, has long been considered
the standard regimen for treating advanced or recurrent endo-
metrial carcinoma. Single-agent chemotherapy with doxorubicin
has achieved response rates in the range of 17–25% (Thigpen et al,
1994). When cisplatin was combined with doxorubicin, two
randomised trials demonstrated improved responses with the
combination. Absolute response rates increased from 25 to 42% in
one study (Thigpen et al, 2004) and from 17 to 43% in the other
trial (Aapro et al, 2003). Unfortunately, neither trial showed
improved survival. The only randomised trial showing a survival
advantage evaluated the addition of paclitaxel to cisplatin plus
doxorubicin, but the three-drug arm was definitely more toxic,
requiring filgrastim support and causing a significant increase in
thrombocytopaenia and neurotoxicity (Fleming et al, 2004).
New schedules with higher efficacy and better tolerability are
strongly needed for the treatment of patients with advanced or
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srecurrent endometrial carcinoma. The use of carboplatin instead of
cisplatin has been suggested to improve tolerability with the same
efficacy (Santin et al, 2004). Pegylated liposomal doxorubicin
(PLD) is an interesting formulation of doxorubicin, in which the
anthracycline is encapsulated in liposomes to obtain pharmaco-
kinetic properties not available with conventional formulation of
the drug: lower plasma concentration peak, lower clearance,
smaller distribution volume, longer half-life, and higher area under
curve (AUC), resulting in a different toxicity profile (Vaage et al,
1993; Sakakibara et al, 1996; Vaage et al, 1997; Safra et al, 2001).
Moreover, the size of the liposomes allows selective accumulation
in the tumour vascular bed following extravasation through the
leaky tumour vasculature (Vaage et al, 1997). Furthermore, the
special coating (pegylation) of the liposomes is associated with
reduced clearance by the mononuclear phagocyte system, thus
helping to maintain active drug concentrations for a long time
(Vaage et al, 1993; Sakakibara et al, 1996; Vaage et al, 1997; Safra
et al, 2001).
A prospective phase II study was conducted by the MITO
(Multicentre Italian Trials in Ovarian Cancer and Gynecologic
Malignancies) cooperative group to describe activity and toler-
ability of the combination of carboplatin plus PLD as first-line
chemotherapy for patients with advanced or recurrent endometrial
carcinoma. The doses of carboplatin AUC 5 and PLD 40mgm
 2
were chosen on the basis of the results of the only study on this
combination published when the study was planned (Verschraegen
et al, 2001).
MATERIALS AND METHODS
Eligibility criteria and baseline assessment
Patients with cytological or histological diagnosis of advanced or
recurrent endometrial carcinoma, with indication for chemother-
apy (stages III and IV, recurrent), age o75 years, an Eastern
Cooperative Oncology Group (ECOG) performance status p2, at
least one measurable lesion and life expectancy of at least 3 months
were eligible. Exclusion criteria were prior or concurrent
malignant cancer (except for non-melanoma skin cancer and for
in situ carcinoma of the uterine cervix, if adequately treated),
previous chemotherapy treatment, inadequate bone marrow
function (white blood cells o4000mm
 3 or platelets
o100000mm
 3); abnormal renal function (total serum creatinine
level 41.25 the upper normal limit), abnormal liver function
(sAST or sALT 41.25 the upper normal limit), heart disease (heart
failure, heart attack in the previous 6 months, atrioventricular
block of any degree, serious arrhythmia). The protocol was
approved by the Ethics Committee of the Coordinating center
(National Cancer Institute, Naples, Italy) and of each participating
centre. Written informed consent was obtained from each enrolled
patient, before study entry.
Baseline evaluation included a complete physical examination
and history, complete blood count and biochemistry with Ca-125
determination, electrocardiogram, chest X-ray, abdomino-pelvic
CT-scan or nuclear magnetic resonance, abdomino-pelvic ultra-
sonography, bone scan with skeletal X-ray as indicated, and other
examination were at the Investigators discretion.
Experimental treatment regimen, dose modifications, and
delays
Patients were treated with carboplatin, AUC 5, intravenously (i.v.),
and PLD, 40mgm
 2, i.v., both drugs given on day 1, every 28 days.
Chemotherapy was administered for a maximum of six cycles.
Carboplatin was dosed in accordance with the Calvert formula
(Calvert et al, 1989), and administered in 250ml physiological
solution, over 30min. Creatinine clearance was calculated from
serum creatinine according to the Cockcroft and Gault formula.
Pegylated liposomal doxorubicin was to be administered after
carboplatin infusion, in 250ml of 5% glucose solution, over 1h.
Criteria for retreatment were: white blood cells X3000mm
 3,
neutrophils X1500mm
 3, platelets X100000mm
 3, absence of
organ toxicity X2 (with the exclusion of hair loss). If these
minimum conditions were not met, the cycle was postponed by 7
days for a maximum of 2 weeks. If the treatment was delayed for
more than 2 weeks, chemotherapy was discontinued due to
unacceptable prolonged toxicity. After the first three cycles, in the
absence of unacceptable toxicity, patients with objective response
or stable disease received further three cycles, for a maximum
number of six cycles.
A 20% dose reduction of both carboplatin and PLD was planned
in case of grade 4 neutropaenia, if lasting more than 7 days, or
platelets o50000mm
 3, if lasting more than 7 days. In case of
creatinine clearance o60ml, the dose of carboplatin was reduced
from AUC 5 to AUC 4. In case of palmar–plantar erythrody-
sesthesia grade 2 or higher, chemotherapy was delayed for up to 2
weeks, until recovery to grade 0–1, and then was applied a 25%
dose reduction. If cutaneous toxicity had not recovered after 2
weeks, PLD had to be withdrawn.
No prophylactic use of G-CSF was recommended. In case of
grade 4 neutropaenia, even without fever, therapeutic and
prophylactic use of G-CSF was allowed.
Assessment of response
Response was evaluated according to Response evaluation criteria
in solid tumours guidelines (Therasse et al, 2000). No independent
review of the responses was planned. Tumour lesions were
categorised as target if they could be accurately measured in at
least one dimension as X20mm with conventional techniques or
as X10mm with spiral CT. All other tumour lesions, including
small lesions and truly non-measurable lesions, were categorised
as nontarget lesions. Response was assessed every three cycles,
with chest X-ray, abdomino-pelvic CT-scan, and other exams,
which were positive at baseline evaluation.
Assessment of toxicity
Toxicity was graded according to National Cancer Institute
Common Toxicity Criteria, version 2.0. (National Cancer Institute,
1999). Physical examination and vital signs were recorded before
each cycle of chemotherapy. Complete blood counts were
performed at baseline and weekly. Laboratory exams (sAST, sALT,
total serum proteins, albumin, bilirubinaemia, alkaline phospha-
tase, lactate dehydrogenase, creatininaemia, blood urea nitrogen,
glycaemia, uricaemia, serum electrolytes) were planned at baseline,
and then repeated before each cycle and 4 weeks after the end of
the last cycle. Left ventricular ejection fraction was assessed by
ultrasound before chemotherapy and every three cycles.
Study design and sample size
The primary end point of the study was the objective response rate
(complete responseþpartial response). A single-stage design for
phase II studies has been used to determine the sample size. With a
error 0.05, power 0.90, minimum acceptable response proportion
(p0) 20% and hoped-for response proportion (p1) 40%, 42 patients
were needed. At the end of the study, at least 13 objective
responses out of the 42 patients treated should be observed, to
define the experimental treatment active.
A secondary end point was the description of treatment
tolerability. Time to progression, defined as the time from the
date of enrolment and the date of the first progression and overall
survival, was defined as the time between the date of enrolment
and the date of death were also described. Time to progression and
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soverall survival were estimated using the Kaplan–Meier method
(Kaplan and Meier, 1958).
RESULTS
From November 2002 to July 2005, 42 patients were enrolled at 5
Italian Institutions. Main baseline characteristics of the enrolled
patients are reported in Table 1. Median age was 64 years (range
31–74). All but one patient had a good ECOG performance status
(0 or 1).
Twenty-seven patients had recurrent disease while 15 were
advanced. Out of the 27 patients with recurrent disease, 14 had
previously received pelvic radiotherapy (50.4Gy) as adjuvant
treatment after surgery. In 6 of these 14 cases also brachitherapy
had been given (15Gy).
Twenty-six patients (62%) completed the planned six cycles. Of
the remaining 16 patients, chemotherapy was interrupted before
the completion for progressive disease or worsening of disease
symptoms (six cases, 14%), for patient’s refusal (one patient, 2%),
for surgical treatment (four patients, 10%), and for unacceptable
toxicity (five patients: four grade 4 haematological toxicity (10%)
and one grade 3 heart rhythm). Eleven out of 167 cycles (6.6%)
were delayed for 1 week due to toxicity.
Details of worst haematological and non-haematological toxicity
are reported in Table 2. One death potentially related to treatment
was recorded: death at home, for unknown reasons, after 6th cycle
(no previous cardiac history, no examination performed due to
sudden death). Grade 3 anaemia was reported in 13 patients (31%),
grade 4 anaemia in one patient, with seven patients requiring RBC
transfusion. Grade 3/4 neutropaenia was observed in 33 and 14%,
respectively, with two patients experiencing febrile neutropaenia.
Grade 3/4 thrombocytopaenia occurred in 17 and 5%, respectively,
with two patients needing platelet transfusion. No case of bleeding
was observed.
Organ toxicity was generally mild: grade 1 heart rhythm two
patients (5%), grade 3 heart rhythm one patient (2%), grade 1
Table 2 Worst toxicity per patient (n¼42)
Worst NCI–CTC grade: number of patients (%)
Toxicity 0 1 2 3 4 5
Anaemia 8 (19%) 6 (14%) 14 (33%) 13 (31%) 1 (2%) —
Leukopenia 9 (21%) 7 (17%) 14 (33%) 6 (14%) 6 (14%) —
Neutropaenia 10 (24%) 5 (10%) 8 (19%) 14 (33%) 6 (14%) —
Febrile neutropaenia 40 (95%) — — 1 (2%) 1 (2%) —
Neutropenic infection 42 (100%) — — — — —
Non-neutropenic infection 41 (98%) 1 (2%) — — — —
Platelets 22 (52%) 7 (17%) 4 (10%) 7 (17%) 2 (5%) —
Platelet transfusion 40 (95%) — — 2 (5%) — —
RBC transfusion 35 (83%) — — 7 (17%) — —
Allergy 42 (100%) — — — — —
Bleeding 42 (100%) — — — — —
Fatigue 30 (71%) 7 (17%) 5 (12%) — — —
Heart rhythm 39 (93%) 2 (5%) — 1 (2%) — —
Heart general 42 (100%) — — — — —
Pulmonary 42 (100%) — — — — —
Fever 42 (100%) — — — — —
Weight loss 42 (100%) — — — — —
Hair loss 35 (83%) 5 (12%) 2 (5%) — — —
Local reaction 41 (98%) 1 (2%) — — — —
Skin (including PPE) 30 (71%) 6 (14%) 4 (10%) 2 (5%) — —
Anorexia 40 (95%) 2 (5%) — — — —
Constipation 31 (74%) 7 (17%) 4 (10%) — — —
Diarrhoea 41 (98%) 1 (2%) — — — —
Nausea 24 (57%) 13 (31%) 5 (12%) — — —
Vomiting 36 (86%) 5 (12%) 1 (2%) — — —
Stomatitis 38 (90%) 1 (2%) 3 (7%) — — —
Liver 41 (98%) — 1 (2%) — — —
Neuropathy 42 (100%) — — — — —
Kidney 40 (95%) 2 (5%) — — — —
Other 39 (93%) 2 (5%)* — — — 1 (2%)**
NCI CTC¼National Cancer Institute Common Toxicity Criteria; PPE¼palmar–plantar erythrodysesthesia; RBC¼red blood cell. *Hyperuricemia; **death at home, for
unknown reasons, after 6th cycle.
Table 1 Baseline characteristics of patients (n¼42)
Median 64
Age (years) Range 31–74 (%)
Recurrent 27 (64)
Advanced 15 (36)
Stage III 8
Stage IV 7
ECOG PS 0 28 (67)
1 13 (31)
2 1 (2)
Grading 1 5 (12)
2 20 (48)
3 15 (36)
NA 2 (4)
Histologic type Endometrioid 35 (83)
Squamous 1 (2)
Serous 4 (10)
Clear cell 2 (5)
NA¼not available; PS¼performance status.
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srenal toxicity two patients (5%), grade 2 liver toxicity one
patient (2%). Complete hair loss was reported in two patients
(5%). No patient experienced neurotoxicity, and no hypersensi-
tivity reaction was recorded. Palmar–plantar erythrodysesthesia
was recorded in 29% of the patients (grade 1 14%, grade 2 10%,
grade 3 5%).
In two patients (5%), restaging was not performed, and thus
were considered as non-responders according to the intention to
treat principle. All the other patients were assessable for response;
three complete (7%) and 22 partial responses (52%) were
observed, for an overall response rate of 59.5% (95% exact CI:
43.3–74.3). Stable disease was achieved in further 13 patients
(31%). According to the study design, the minimum number of
response needed to define the treatment active has been obtained.
As on September 2006, 32 disease progressions were recorded.
Median progression-free survival was 52.9 weeks (95% CI 44–
71.9). With 20 deaths recorded, median survival was 80.1 weeks
(95% CI 76.6-NA). (Median follow-up of alive patients was 74
weeks.)
DISCUSSION
This phase II study shows the feasibility of the combination of
carboplatin AUC 5 and PLD, 40mgm
 2 in advanced or recurrent
endometrial cancer. Promising activity of this combination has
been observed.
Treatment of advanced endometrial cancer remains a difficult
task for the oncologist due to both the small number of studies
performed and the absence of a clear indication of the best
therapeutical option to adopt in a population of patients that are
often elderly and have associated comorbidities.
Cisplatin–doxorubicin before (Aapro et al, 2003; Thigpen et al,
2004), and cisplatin–doxorubicin–paclitaxel later (Fleming et al,
2004), are the chemotherapy schedules most frequently used
worldwide. Particularly, the latter is associated with a toxicity
profile that frequently makes it impossible to be given to
unselected patients outside a clinical trial (Fleming et al, 2004).
Furthermore, paclitaxel is not approved for the use in endometrial
cancer in most European countries, including Italy. It is commonly
believed that there is a need for new schedules of chemotherapy
agents that combine efficacy and tolerability, in the attempt to
minimise toxicity and maximise quality of life for patients in this
setting.
The combination of carboplatin and PLD has been developed in
ovarian cancer for platinum-sensitive recurrences (Ferrero et al,
2007) and is currently under investigation in first-line (Pignata
et al, 2006) ovarian cancer, where it has been proven to be safe and
effective. The AGO group has recently published their experience
with this combination in patients with advanced gynaecologic
malignancies, including 19 patients with endometrial cancer,
confirming the safe tolerability profile and suggesting a possible
advantage in terms of safety compared to the commonly used
cisplatin–paclitaxel regimens (Du Bois et al, 2006).
Carboplatin and PLD were given to 42 patients in our study. We
present here the activity data showing a very interesting response
rate of 59.5% (7% complete response) that is at the higher range of
activity previously reported for this disease.
These figures were obtained with an acceptable toxicity profile.
Toxicity was mainly haematological while the non-haematological
toxicity profile was particularly safe. The haematological events
were not associated with a significant number of delays in
chemotherapy administration and the majority of the cycles were
given on time. Neutropaenia and thrombocytopaenia were
frequent, with two cases of febrile neutropaenia. No symptomatic
thrombocytopaenia was reported. The low rate of neurotoxicity is
interesting, given that neurotoxicity is one of the major factors in
non-compliance with standard first-line chemotherapy. In addi-
tion, the low rate of hair loss could represent a significant
advantage compared to the standard regimens of cisplatin,
doxorubicin, and paclitaxel.
In this study, liposomal doxorubicin was given every 4 weeks
at the dose of 40mgm
 2 based on the information present
in the literature at the beginning of the study (Verschraegen et al,
2001). However, there is now a significant amount of data, at least
in ovarian cancer, suggesting that a 3-weekly schedule of
carboplatin AUC 5 and liposomal doxorubicin 30mgm
 2 is
associated with an improved toxicity profile, particularly regarding
haematological events, thus suggesting further investigation of
this schedule also in patients with endometrial cancer (Pignata
et al, 2006).
Independently from the dose chosen, 30 or 40mgm
 2, and of
the schedule, 3- or 4-weekly, we think that the activity of the
combination of carboplatin and PLD observed in the present study
is at the higher range reported in the literature comparing
favourably with platinum-based and paclitaxel-based doublets and
triplets (Fleming et al, 2004; Thigpen et al, 2004). This finding,
combined with the safe toxicity profile found in our patients,
suggest that a phase III study in order to compare this
chemotherapy with the standard cisplatin-based treatment may
be recommended.
In conclusion, the combination of carboplatin and PLD shows
good activity and favourable toxicity as first-line chemotherapy of
patients with advanced endometrial carcinoma, deserving further
studies in this setting.
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